CytomX Therapeutics (CTMX) Free Cash Flow Growth (3y) (2017 - 2026)
CytomX Therapeutics (CTMX) Free Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 31.42% |
| 10 | CytomX Therapeutics | 602.73 Mn | 256.02 Mn | - | -68.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68.06% |
| Dec 31, 2025 | -145.99% |
| Sep 30, 2025 | 23.36% |
| Jun 30, 2025 | 23.06% |
| Mar 31, 2025 | 20.46% |
| Dec 31, 2024 | 14.01% |
| Sep 30, 2024 | 11.53% |
| Jun 30, 2024 | 11.47% |
| Mar 31, 2024 | 5.42% |
| Dec 31, 2023 | -11.02% |
| Sep 30, 2023 | 10.50% |
| Jun 30, 2023 | -31.32% |
| Mar 31, 2023 | 29.73% |
| Dec 31, 2022 | 62.63% |
| Sep 30, 2022 | -10.05% |
| Jun 30, 2022 | 9.81% |
| Mar 31, 2022 | -0.96% |
| Dec 31, 2021 | -5.07% |
| Sep 30, 2021 | -59.44% |
| Jun 30, 2021 | -1.53% |